High-potency P2Y12 receptor inhibitor use, notably prasugrel after 2019, continues to rise among patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Real-world prescribing practices for P2Y12 inhibitors in AMI patients undergoing PCI are evolving, demonstrating increased adoption of high-potency agents like prasugrel in response to recent clinical trials and guideline updates.
Absolute Event Rate: 0% vs 0%
Among patients with AMI undergoing PCI, the use of high-potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR-REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice.
Fath et al. (Wed,) reported a other. High-potency P2Y12 receptor inhibitor use, notably prasugrel after 2019, continues to rise among patients with acute myocardial infarction undergoing percutaneous coronary intervention.